”The positive results of the of the MPACT trial resulted in the approval of nab-paclitaxel plus gemcitibine as a first-line treatment for MPC. However the effectiveness of this regimen against localised pancreatic cancer remains unknown.”
Keep trying...boy it really must have irked you when EU approval was granted...
OSL Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)